NasdaqGM:CRSPBiotechs
Did CRISPR’s Cash Raise, Casgevy Launch and Insider Buying Just Shift CRISPR Therapeutics' (CRSP) Investment Narrative?
In recent weeks, CRISPR Therapeutics raised US$600 million via convertible notes due 2031, while analysts reiterated positive views and corporate insiders, including the CMO, increased share purchases.
Alongside its first commercial revenue from Casgevy and a cash position above US$2 billion, the company outlined multiple gene-editing programs with key clinical readouts planned through 2026.
We’ll now consider how this bolstered cash runway and advancing gene-editing pipeline affect CRISPR...